Back to Journals » OncoTargets and Therapy » Volume 9

Association between L55M polymorphism in Paraoxonase 1 and cancer risk: a meta-analysis based on 21 studies

Authors Chen L, Lu W, Fang L, Xiong H, Wu X, Zhang M, Wu S, Yu D

Received 23 September 2015

Accepted for publication 21 December 2015

Published 4 March 2016 Volume 2016:9 Pages 1151—1158

DOI https://doi.org/10.2147/OTT.S96990

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 2

Editor who approved publication: Dr Jianmin Xu


Lei Chen,1,* Wei Lu,2,* Lu Fang,1 Hu Xiong,3 Xun Wu,4 Meng Zhang,2 Song Wu,2 Dexin Yu1

1Department of Urology, The Second Affiliated Hospital of Anhui Medical University, 2Department of Urology, Anhui Medical University Graduate School, Hefei, Anhui, 3Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 4Department of Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Abstract:
L55M polymorphism in Paraoxonase 1 (PON1) has been regarded as a risk factor for many cancer types. Nevertheless, the results remain controversial and inconclusive. We therefore performed a meta-analysis of all eligible case–control studies to evaluate the association between L55M polymorphism and cancer risk. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the associations. Finally, a total of 5,627 cases and 6,390 controls, arising from 21 case–control studies, were enrolled in our study. Significant associations between PON1-L55M polymorphism and overall cancer risk were identified in all genetic models. In the stratified analyses by cancer type, PON1-L55M polymorphism was a risk factor for breast cancer in all genetic models, prostate cancer in the heterozygote model (ML vs LL: OR =1.304, 95% CI =1.049–1.620, Pheterogeneity=0.067), and ovarian cancer in the recessive model (MM vs ML/LL: OR =1.526, 95% CI =1.110–2.097, Pheterogeneity=0.464). Similarly, an increased risk was also identified for the Caucasian population in the heterozygote comparison and homozygote models, and hospital-based controls in all genetic models. To sum up, our study suggests that the PON1-L55M allele increased the risk of cancer. Future well-designed studies with larger sample sizes are warranted to further verify these findings.

Keywords:
Paraoxonase 1, L55M, polymorphism, cancer, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]